Overview

A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Status:
Not yet recruiting
Trial end date:
2025-06-10
Target enrollment:
Participant gender:
Summary
A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome).
Phase:
Phase 4
Details
Lead Sponsor:
Zydus Lifesciences Limited